Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. Toorop AA, et al. Among authors: hoitsma e. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):392-400. doi: 10.1136/jnnp-2023-332119. J Neurol Neurosurg Psychiatry. 2024. PMID: 37963723 Clinical Trial.
Personality traits are not associated with changes in employment status over 3 years in persons with multiple sclerosis.
van der Hiele K, van Egmond E, van Gorp D, Jongen PJ, Reneman MF, van der Klink J, Beenakker E, van Eijk J, Frequin S, Hoitsma E, Gerlach O, Mostert JP, Verhagen W, Heerings M, Middelkoop H, Visser LH. van der Hiele K, et al. Among authors: hoitsma e. Mult Scler J Exp Transl Clin. 2022 Dec 19;8(4):20552173221145576. doi: 10.1177/20552173221145576. eCollection 2022 Oct-Dec. Mult Scler J Exp Transl Clin. 2022. PMID: 36570872 Free PMC article.
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
Toorop AA, van Kempen ZLE, Steenhuis M, Nielsen J, Sinnige LGF, van Dijk G, Roosendaal CM, Arnoldus EPJ, Hoitsma E, Lissenberg-Witte BI, de Jong BA, Oosten BWV, Strijbis EMM, Uitdehaag BMJ, Rispens T, Killestein J; NEXT-MS study group. Toorop AA, et al. Among authors: hoitsma e. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):482-486. doi: 10.1136/jnnp-2022-330467. Epub 2023 Jan 13. J Neurol Neurosurg Psychiatry. 2023. PMID: 36639226
Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis.
van Egmond EEA, van der Hiele K, de Rooij MJ, van Gorp DAM, Jongen PJ, van der Klink JJL, Reneman MF, Beenakker EAC, van Eijk JJJ, Frequin STFM, de Gans K, Hoitsma E, Gerlach OHH, Mostert JP, Verhagen WIM, Visser LH, Middelkoop HAM. van Egmond EEA, et al. Among authors: hoitsma e. IBRO Neurosci Rep. 2024 Apr 15;16:518-526. doi: 10.1016/j.ibneur.2024.04.002. eCollection 2024 Jun. IBRO Neurosci Rep. 2024. PMID: 38660124 Free PMC article.
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Toorop AA, Wessels MHJ, Gelissen LMY, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert JP, Wokke BHA, Kalkers NF, Hoogervorst ELJ, van Eijk JJJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, van Dijk GW, Bouvy WH, Strijbis EMM, van Oosten BW, de Jong BA, Lissenberg-Witte BI, Rispens T, Uitdehaag BMJ, Killestein J, van Kempen ZLE. Toorop AA, et al. Among authors: hoitsma e. J Neurol Sci. 2024 Jul 15;462:123102. doi: 10.1016/j.jns.2024.123102. Epub 2024 Jun 22. J Neurol Sci. 2024. PMID: 38925067 Free article. Clinical Trial.
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: hoitsma e. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: hoitsma e. JAMA Neurol. 2024 Dec 9. doi: 10.1001/jamaneurol.2024.4164. Online ahead of print. JAMA Neurol. 2024. PMID: 39652340
43 results